Proteasome inhibitors in the treatment of multiple myeloma

Abstract

Treatment strategies for multiple myeloma have undergone significant changes in the last two decades, resulting in essential changes in the prognosis of patients. The introduction of a new class of drugs called proteasome inhibitors, the first representative of which, bortezomib, was approved by the US FDA for use in multiple myeloma in 2003, also contributed significantly to this.

Keywords

• multiple myeloma
• therapy proteasome inhibitors
• bortezomib
• carfilzomib
• ixazomib